These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32499264)

  • 1. Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.
    Wang J; Wu DX; Meng L; Ji G
    BMJ Open; 2020 Jun; 10(6):e034685. PubMed ID: 32499264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 4. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
    Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
    Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
    BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
    Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
    Jiang Z; Zhou A; Sun Y; Zhang W
    BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
    Yamada Y; Koizumi W; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Hyodo I
    Cancer Sci; 2019 Sep; 110(9):2875-2883. PubMed ID: 31254422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
    Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
    BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
    Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.
    Chu Y; He X; Xue Y; Jiang H; Zhu C; Qi C; Zhang X; Chen D; Dai H; Xian Q; Zhu W
    Front Immunol; 2024; 15():1448485. PubMed ID: 39253086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
    Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
    Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
    Dai X; Zhang X; Wang C; Jiang J; Wu C
    Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
    Duh D; Warnez M
    J Pharm Belg; 2013 Dec; (4):35-6. PubMed ID: 24449972
    [No Abstract]   [Full Text] [Related]  

  • 19. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
    Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
    Gastric Cancer; 2003; 6 Suppl 1():34-9. PubMed ID: 12775018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
    Matt P; van Zwieten-Boot B; Calvo Rojas G; Ter Hofstede H; Garcia-Carbonero R; Camarero J; Abadie E; Pignatti F
    Oncologist; 2011; 16(10):1451-7. PubMed ID: 21963999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.